S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
PVCT · PROVECTUS BIOPHARMACEUTICALS INC
OTC MARKETS - Real Time Price • USD
Provectus Biopharmaceuticals Inc (PVCT)
OTC MARKETS
Pharmaceuticals
$0.05
+0.00
(+2.04%)
● Overnight
DAY'S RANGE
$0.05
$0.05
$0.05
52-WEEK RANGE
$0.05
$0.04
$0.08
What's happening
- PVCT is up 2.04% today, trading at $0.05. — Live quote
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
PVCT
-10.73%
vs S&P 500
-23.51%
1-YEAR RETURN
PVCT
-30.69%
vs S&P 500
-45.26%
6-MONTH RETURN
PVCT
-5.85%
3-MONTH RETURN
PVCT
-16.13%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2024-10-26 (Q3 2024)
$0.00
Est. $—
2023-10-26 (Q3 2023)
$0.00
Est. $—
2013-01-26 (Q4 2012)
$-0.02
Est. $-0.03
BEAT +34.6%
2012-10-26 (Q3 2012)
$-0.02
Est. $-0.03
BEAT +34.6%
Valuation Measures & Ratios
Enterprise Value4$23.2M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)45.57
Price / Book71.35
EV4 / Revenue50.45
EV4 / EBITDA—
Profit Margin-1376.86%
Operating Margin-1344.86%
Return on Equity (ROE8)-304.42%
Return on Assets (ROA9)-599.57%
Avg Volume (3M)143,380
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short801,174
Change from Prior Settlement+0.00%
% of Float—
Days to Cover (Short Ratio)4.82
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -1376.9%. Finnhub fundamentals ↗
- Trailing 52-week price return is -30.7%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on PVCT
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $57.5K | $278.6K | $109.7K | $255.0K | $238.1K |
| Operating income | -$938.7K | -$1.2M | -$1.3M | -$1.8M | -$1.1M | -$955.7K | -$794.9K | -$447.3K |
| Net income | -$982.6K | -$1.3M | -$1.3M | -$1.8M | -$1.1M | -$1.0M | -$846.8K | -$504.0K |
| EPS (diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating margin | — | — | — | -$3.1K | -$394 | -$871 | -$312 | -$188 |
| Net margin | — | — | — | -$3.2K | -$409 | -$924 | -$332 | -$212 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.5M | $577.6K | $697.5K | $419.9K | $722.4K | $666.3K | $1.0M | $802.0K |
| Total liabilities | $7.8M | $7.3M | $7.0M | $6.6M | $6.6M | $5.7M | $7.0M | $6.2M |
| Stockholders' equity | -$6.3M | -$6.7M | -$6.3M | -$6.2M | -$5.9M | -$5.1M | -$6.0M | -$5.4M |
| Total current assets | $1.4M | $460.4K | $567.9K | $278.0K | $568.3K | $649.5K | $976.8K | $760.0K |
| Total current liabilities | $7.7M | $7.2M | $6.9M | $6.5M | $6.5M | $5.7M | $7.0M | $6.2M |
| Cash & equivalents | $1.2M | $223.9K | $251.3K | $72.5K | $385.9K | $390.4K | $307.4K | $187.5K |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Other current assets | — | — | $71.4K | $90.8K | $2.8K | — | $236.4K | — |
| Property, plant & equipment | $2.1K | $2.5K | $3.0K | $3.5K | $3.9K | $4.4K | $4.9K | $5.3K |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $932.0K | $815.3K | $716.2K | $1.2M | $1.3M | $744.0K | $1.1M | $1.4M |
| Deferred revenue (current) | — | — | — | — | — | $57.5K | $336.1K | $350.4K |
| Short-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $420.3K | $420.3K | $420.3K | $420.3K | $420.3K | $420.3K | $420.3K | $420.3K |
| Retained earnings | -$265.1M | -$264.1M | -$262.9M | -$261.7M | -$260.4M | -$258.6M | -$257.4M | -$255.1M |
| Accumulated other comprehensive income (loss) | -$59.8K | -$59.9K | -$60.2K | -$60.3K | -$60.4K | -$60.7K | -$60.7K | -$60.2K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$358.2K | -$357.6K | -$869.6K | -$839.9K | -$523.1K | -$1.1M | -$912.0K | -$565.0K |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | $1.3M | $329.9K | $1.0M | $495.9K | $469.8K | $1.1M | $788.4K | $589.4K |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Share-based compensation | $305.9K | $306.1K | $287.6K | $312.8K | $322.1K | $315.1K | $1.3M | — |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $336.1K | $617.1K | $557.7K | $989.0K | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$5.3M | -$4.5M | -$2.9M | -$3.4M | -$4.7M |
| Net income | -$5.4M | -$4.7M | -$3.1M | -$3.6M | -$5.5M |
| EPS (diluted) | $-0.01 | $-0.01 | $-0.01 | $-0.01 | — |
| EPS (basic) | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 |
| Operating margin | -$1.6K | -$734 | -$520 | -$347 | — |
| Net margin | -$1.6K | -$767 | -$556 | -$359 | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $697.5K | $1.0M | $1.4M | $2.0M | $3.5M |
| Total liabilities | $7.0M | $7.0M | $9.0M | $8.3M | $7.7M |
| Stockholders' equity | -$6.3M | -$6.0M | -$7.6M | -$6.2M | -$4.2M |
| Total current assets | $567.9K | $976.8K | $1.4M | $1.9M | $3.4M |
| Total current liabilities | $6.9M | $7.0M | $9.0M | $8.2M | $7.7M |
| Cash & equivalents | $251.3K | $307.4K | $76.6K | $21.6K | $683.0K |
| Accounts receivable | — | — | $476 | $394 | $5.1K |
| Other current assets | $71.4K | $236.4K | — | — | — |
| Property, plant & equipment | $3.0K | $4.9K | $12.0K | $20.9K | $31.8K |
| Intangible assets | — | — | — | — | — |
| Other non-current assets | — | — | — | — | — |
| Accounts payable | $716.2K | $1.1M | $1.7M | $2.1M | $1.3M |
| Deferred revenue (current) | — | $336.1K | $953.2K | $1.5M | $2.5M |
| Short-term debt | — | — | — | — | — |
| Common stock & paid-in capital | $420.3K | $420.3K | $419.5K | $419.5K | $419.4K |
| Retained earnings | -$262.9M | -$257.4M | -$252.7M | -$249.6M | -$246.0M |
| Accumulated other comprehensive income (loss) | -$60.2K | -$60.7K | -$60.2K | -$35.7K | -$34.5K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$3.3M | -$3.3M | -$2.6M | -$3.0M | -$1.0M |
| Investing cash flow | — | — | — | — | — |
| Financing cash flow | $3.1M | $2.7M | $2.2M | $1.4M | $4.0M |
| Capital expenditures | — | — | — | — | — |
| Share-based compensation | $1.2M | $1.3M | $2.9K | $3.0K | $23.7K |
| Purchases of investments | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding PVCT as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Insider activity is not available for this symbol right now.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 05:56 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 4 | 2026-10-10 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-03 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-18 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-11 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-08-26 | 4 | 2026-08-26 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-07-01 | 8-K | 2026-06-30 | View on SEC.gov → |
| 2026-06-30 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-06-30 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-06-30 | 4 | 2026-06-30 | View on SEC.gov → |
Recent news
Headlines about PVCT (PROVECTUS BIOPHARMACEUTICALS INC). Links open the publisher — we don’t host full articles.
-
Form 4 Provectus Biopharmaceuticals Inc: Edward Pershing (Director, 10% Owner, CEO) For: 10 October
Investing.com UK · 2026-10-17 -
VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase
Yahoo Finance · 2026-07-22 -
Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose
Yahoo Finance · 2026-07-07 -
Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
Yahoo Finance · 2026-06-30 -
Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)
Yahoo Finance · 2026-06-25 -
Provectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call - Slideshow
Seeking Alpha · 2026-06-24 -
Provectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call Transcript
Seeking Alpha · 2026-06-18 -
Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
Yahoo Finance · 2026-05-18
No headlines in this category right now — try “All”.